Rituximab in refractory and relapsed dermatomyositis and polymyositis: Comment on the article by oddis et al

Arthritis and Rheumatism

Volumn 65, Issue 9, 2013, Pages 2497-2498

  Cuttner, Janet ^a   Spiera, Harry ^a   Gorevic, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; RITUXIMAB;

DERMATOMYOSITIS; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; LETTER; OUTCOME ASSESSMENT; POLYMYOSITIS; PRIORITY JOURNAL; REFRACTORY PERIOD; RELAPSE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; POLYMYOSITIS;

EID: 84883228943     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38018     Document Type: Letter

References (6)

1. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al, and the RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
2. De Visser M,. The efficacy of rituximab in refractory myositis: the jury is still out [editorial]. Arthritis Rheum 2013; 65: 303-6.
3. Levine TD,. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
4. Majmudar S, Hall HA, Zimmermann B,. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 2009; 15: 338-40.
5. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology 2010; 49: 1683-93.
6. Miller FW,. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71 Suppl 2: i82-5.